Poxel provides an update on its financial position for the second quarter and first half of 2024 and announces the rescheduling of its annual general meeting

Lyon, france--(business wire)--regulatory news: poxel sa (euronext : poxel - fr0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (nash) and rare metabolic disorders, today publishes its cash position, provides an update on its financial situation for the second quarter and first half of 2024, ending june 30, 2024, reviews its activities on june 30, 2024 and.
GM Ratings Summary
GM Quant Ranking